Use of advanced heart failure therapies in Duchenne muscular dystrophy.
Duchenne muscular dystrophy
Dystrophic cardiomyopathy
Heart failure
Journal
Progress in pediatric cardiology
ISSN: 1058-9813
Titre abrégé: Prog Pediatr Cardiol
Pays: Netherlands
ID NLM: 9209539
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
ppublish
Résumé
As survival and neuromuscular function in Duchenne Muscular Dystrophy (DMD) improve with glucocorticoid therapy and respiratory advances, the proportion of cardiac deaths is increasing. Little is known about the use and outcomes of advanced heart failure (HF) therapies in this population. A retrospective cohort study of 436 males with DMD was performed, from January 1, 2005-January 1, 2018, with the primary outcome being use of advanced HF therapies including: implantable cardioverter defibrillator (ICD), left ventricular assist device (LVAD), and heart transplantation (HTX). Nine subjects had an ICD placed, 2 of whom (22.2%) had appropriate shocks for ventricular tachycardia; 1 and 968 days after implant, and all of whom were alive at last follow-up; median 18 (IQR: 12.5-25.5) months from implant. Four subjects had a LVAD implanted with post-LVAD survival of 75% at 1 year; 2 remaining on support and 1 undergoing HTX. One subject was bridged to HTX with ICD and LVAD and was alive at last follow-up, 53 months after HTX. Advanced HF therapies may be used effectively in select subjects with DMD. Further studies are needed to better understand risk stratification for ICD use and optimal candidacy for LVAD implantation and HTX, with hopes of improving cardiac outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
As survival and neuromuscular function in Duchenne Muscular Dystrophy (DMD) improve with glucocorticoid therapy and respiratory advances, the proportion of cardiac deaths is increasing. Little is known about the use and outcomes of advanced heart failure (HF) therapies in this population.
METHODS
METHODS
A retrospective cohort study of 436 males with DMD was performed, from January 1, 2005-January 1, 2018, with the primary outcome being use of advanced HF therapies including: implantable cardioverter defibrillator (ICD), left ventricular assist device (LVAD), and heart transplantation (HTX).
RESULTS
RESULTS
Nine subjects had an ICD placed, 2 of whom (22.2%) had appropriate shocks for ventricular tachycardia; 1 and 968 days after implant, and all of whom were alive at last follow-up; median 18 (IQR: 12.5-25.5) months from implant. Four subjects had a LVAD implanted with post-LVAD survival of 75% at 1 year; 2 remaining on support and 1 undergoing HTX. One subject was bridged to HTX with ICD and LVAD and was alive at last follow-up, 53 months after HTX.
CONCLUSION
CONCLUSIONS
Advanced HF therapies may be used effectively in select subjects with DMD. Further studies are needed to better understand risk stratification for ICD use and optimal candidacy for LVAD implantation and HTX, with hopes of improving cardiac outcomes.
Identifiants
pubmed: 31360053
doi: 10.1016/j.ppedcard.2019.01.001
pmc: PMC6663084
mid: NIHMS1034748
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11-14Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK114477
Pays : United States
Déclaration de conflit d'intérêts
Declaration of interest Carol A. Wittlieb-Weber, MD: None. Chet R. Villa, MD: None. Matthew J. Bock, MD: None. Katheryn E. Gambetta, MD: None. Jonathan N. Johnson, MD: None. Ashwin K. Lal, MD: None. Kurt R. Schumacher, MD: None. Sabrina P. Law, MD: None. Shriprasad R. Deshpande, MD, MS: None. Shawn C. West, MD, MSc: None. Joshua M. Friedland-Little, MD: None. Irene D. Lytrivi, MD: None. Michael A. McCulloch, MD: None. Ryan J. Butts, MD: None. David R. Weber, MD, MSCE: Consulted for Marathon Pharmaceuticals. Kenneth R. Knecht, MD: None.
Références
J Heart Lung Transplant. 2010 Apr;29(4):432-8
pubmed: 19864165
Respir Care. 2011 Jun;56(6):744-50
pubmed: 21333078
Int J Cardiol. 1990 Mar;26(3):271-7
pubmed: 2312196
J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35
pubmed: 23500286
Ann Phys Rehabil Med. 2013 Sep;56(6):443-54
pubmed: 23876223
ASAIO J. 2014 Mar-Apr;60(2):246-8
pubmed: 24577373
Neuromuscul Disord. 2014 Jun;24(6):482-91
pubmed: 24780148
J Child Neurol. 2015 Sep;30(10):1275-80
pubmed: 25414237
Pediatrics. 2015 Mar;135(3):513-21
pubmed: 25687144
Circulation. 2015 May 5;131(18):1590-8
pubmed: 25940966
J Thorac Cardiovasc Surg. 2017 Mar;153(3):669-674
pubmed: 27692952
ESC Heart Fail. 2017 Aug;4(3):379-383
pubmed: 28772036
J Heart Lung Transplant. 2018 Jan;37(1):38-45
pubmed: 28965736
Neuromuscul Disord. 1993 May;3(3):201-6
pubmed: 7691292
Am Heart J. 1994 Mar;127(3):618-23
pubmed: 8122611